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OBJECTIVE — To compare the improvements in glycemic control associated with transi-
tioning to insulin pump therapy in patients using continuous glucose monitoring versus stan-
dard blood glucose self-monitoring.
RESEARCH DESIGN AND METHODS — The RealTrend study was a 6-month, ran-
domized, parallel-group, two-arm, open-label study of 132 adults and children with uncon-
trolled type 1 diabetes (A1C 8%) being treated with multiple daily injections. One group was
ﬁtted with the Medtronic MiniMed Paradigm REAL-Time system (PRT group), an insulin pump
with integrated continuous subcutaneous glucose monitoring (CGM) capability, with instruc-
tions to wear CGM sensors at least 70% of the time. Conventional insulin pump therapy was
initiated in the other group (continuous subcutaneous insulin infusion [CSII] group). Outcome
measures included A1C and glycemic variability.
RESULTS — Atotalof115patientscompletedthestudy.Betweenbaselineandtrialend,A1C
improved signiﬁcantly in both groups (PRT group 0.81  1.09%, P  0.001; CSII group
0.57  0.94%, P  0.001), with no signiﬁcant difference between groups. When the 91
patients who were fully protocol-compliant (including CGM sensor wear 70% of the time)
wereconsidered,A1CimprovementwassigniﬁcantlygreaterinthePRTgroup(P0.004)(PRT
group 0.96  0.93%, P  0.001; CSII group 0.55  0.93%, P  0.001). Hyperglycemia
parameters decreased in line with improvements in A1C with no impact on hypoglycemia.
CONCLUSIONS — CGM-enabledinsulinpumptherapyimprovesglycemiamorethancon-
ventional pump therapy during the ﬁrst 6 months of pump use in patients who wear CGM
sensors at least 70% of the time.
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T
he long-term clinical beneﬁt of
tight glycemic control in type 1 di-
abetic patients has been demon-
strated in several reports by the
Diabetes Control and Complications
Trial (1,2). To achieve this goal, insulin
analogs, basal-bolus multiple daily in-
jections (MDI), and insulin pumps for
continuous subcutaneous insulin infu-
sion (CSII) have proved to be important
tools for lowering glucose variability
and improving glycemic control, lead-
ing to higher treatment satisfaction in
patients with type 1 diabetes (3–5).
Nevertheless, intensive treatment of
type 1 diabetes often does not succeed in
achieving target A1C levels 7.0% (6).
Increased self-monitoring of blood glu-
cose (SMBG) levels is correlated with bet-
ter A1C levels (7,8), but for practical
reasons most patients do not perform
more than ﬁve to seven glucose measure-
ments per day. Consequently, postpran-
dial hyperglycemia and nocturnal
hypoglycemia often remain unnoticed,
even in individuals with well-controlled
diabetes (9–11). Hence, detecting and
treating these events might improve the
patient’sglycemiccontrolandhaveanim-
pact on quality of life.
Continuous glucose monitoring
(CGM) provides information from a
subcutaneous glucose sensor on inter-
stitialglucoselevels.AtypicalCGMsys-
tem incorporates alarms for high and
low glucose levels and displays glucose
trend information graphically, allowing
patients to anticipate hypo- and hyper-
glycemic events. Recent studies have
shown that wearing such devices is as-
sociated with improved glycemic con-
trol in patients undergoing intensive
therapy for type 1 diabetes (12,13) and
in patients treated by CSII (14); how-
ever, no study has investigated the ben-
eﬁt of CGM in patients with poor
metabolic control using MDI upon ini-
tiation of pump therapy. In this trial we
randomly initiated pump therapy in pa-
tients with insufﬁcient metabolic con-
trol despite optimized basal-bolus
injection regimens with either the Mini-
Med Paradigm REAL-Time insulin
pump (PRT), an insulin pump that can
receive and display CGM data from a
separate subcutaneous glucose sensor,
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glycemic outcomes after 6 months.
RESEARCH DESIGN AND
METHODS— A total of 132 patients
(51 children and 81 adults) with type 1
diabetes were recruited in eight centers
(six adult and two pediatric centers). In-
clusion criteria required age between 2
and 65 years, type 1 diabetes diagnosed
for12months,follow-upbytherespec-
tive investigator for at least 3 months,
A1C 8%, and treatment with basal/
bolus MDI with rapid insulin analogs at
mealtimes. Unbiased biochemical hyper-
and hypoglycemia parameters were col-
lected using a blinded Holter-type CGM
deviceatthebeginningandtheendofthe
trial. Patients randomly assigned into the
PRT group agreed to wear an unblinded
glucose sensor during at least 70% of the
study period. All patients continued to
perform ﬁngerstick measurements for
glucoseself-monitoringastheydidbefore
the study.
The trial was approved by the ethics
committee,Comite ´ deProtectiondesPer-
sonnes Sud-Me ´diterrane ´e II. All patients
(ortheparentsofminorpatients)readthe
patient information and signed informed
consent forms.
Study treatment
Physicians and patients were blinded to
centralized A1C data from baseline to
completion of the study. A1C levels were
measured at screening, baseline, 3
months, and 6 months.
Two weeks after screening (visit 1),
eligible patients were randomly assigned
to one of the two groups (PRT or CSII)
and ﬁtted with a Holter-type CGM device
for 3 days. Blinded CGM data were re-
trieved at the end of this period (visit 2).
Patients in the PRT group were asked to
start using only the (unblinded) CGM
functionoftheirinsulinpumpatthistime
andwerefreetousetheCGMinformation
provided to them as they desired, while
continuing MDI treatment for 9 days. De-
fault settings for the high- and low-
glucose alarms could be adjusted by the
physician for individual patients.
At baseline (visit 3, 12 days after ran-
domization), insulin pump therapy was
initiated in both groups. Patients in the
PRT group started using the pump func-
tion of their device, whereas patients in
the CSII group were ﬁtted with a
Medtronic MiniMed Paradigm 512/712
insulin pump. All patients continued to
usetheirusualbloodglucosemetertoob-
tain at least three readings daily. Patients
in the PRT group were required to use
glucose sensors at least 70% of the time
and replace the sensor every 3 days and
were instructed on appropriate responses
to CGM information. A conﬁrmatory
blood glucose reading served as reference
for therapeutic decisions.
One month after pump therapy initi-
ation (visit 4), device data were down-
loaded for both groups, and patients
discussed treatment with the physician.
Therapy could be adjusted for all patients
and alarm targets reset for the PRT group.
After3monthsofpumptherapy(visit
5), pump and CGM data were down-
loaded again, blood samples were taken
for A1C determination, and treatment
guidelines were adjusted as needed.
Three days before the ﬁnal study
visit after 6 months of pump therapy
(visit 6), all patients again wore a
blinded Holter-type CGM device.
Blinded CGM, PRT, and CSII data were
downloaded at study end.
The primary objective of the trial was
to determine whether pump therapy ini-
tiation in patients with A1C values 8%,
being currently treated with MDI, could
resultinimprovedmetaboliccontrolafter
24 weeks of continuous use of either a
sensor-augmented or a conventional in-
sulin pump. The secondary objective was
toevaluatechangeinglycemicvariability.
The primary outcome was A1C change
from baseline (visit 3) to 6 months (visit
6). Secondary outcomes included mean
glucose change and descriptive parame-
ters for biochemical hyperglycemia
(190 mg/dl) and hypoglycemia (70
mg/dl). Daily insulin use was also
compared.
Thesamplesizecalculationwasbased
on change in A1C levels between baseline
and trial end. A difference of 0.5% be-
tween the treatment groups was consid-
eredclinicallymeaningful.Tohavea95%
chance of detecting a 0.5% difference
with an assumed SD of 0.9, using a two-
sided two-sample t test with a power of
80%, 52 patients were required for each
group. A total of 132 patients were ran-
domly assigned to allow for a normal
dropout rate. Because of the nature of the
treatments, the study was not blinded.
Statistical analysis
The primary covariance analysis was
based on the comparison of A1C changes
between the PRT and CSII groups using
the last observation carried forward
method on the full analysis set (FAS) of
patients (all patients with two A1C re-
sults from baseline to the end of the
study). P  0.05 was considered statis-
tically signiﬁcant. Analyses were ad-
justedforageaspatientswererandomly
assigned within the age-groups: 19
and 19 years. In light of sensor use
heterogeneity in the PRT group, a sepa-
rate analysis was conducted using data
from only those subjects who adhered
to the protocol requirements (the per-
protocol data subset).
Secondary outcomes analyzed the
changes in glucose concentration (hyper-
glycemia and hypoglycemia above and
below the target range) calculated from
blinded CGM data using the covariance
analysismodel.Dailyuseofinsulincalcu-
lated from pump downloads was com-
pared between groups using an ANOVA
adjusted for age-groups.
RESULTS— Between May 2006 and
December 2007, 148 patients were as-
sessed for eligibility and 132 (81 adults
and 51 children) fulﬁlling the inclusion
criteria were randomly assigned. The
safety population (n  128) was identical
to the randomized population except for
four adults who withdrew before visit 3.
The FAS population (n  115) excluded
an additional 13 patients who did not
have A1C measured after the baseline
visit.TheFASpopulationincluded55pa-
tients in the PRT arm (22 children and 33
adults)andthe60patientsintheCSIIarm
(24 children and 36 adults). Analysis on
thispopulationwasintentiontotreat.The
per protocol population excluded 24 FAS
patients because of major protocol devia-
tions (1 screening failure in the CSII
group and 23 patients in the PRT group
whofailedtowearglucosesensorsatleast
70% of the time). The per protocol pop-
ulation included 32 patients in the PRT
group (11 children and 21 adults) and 59
patients in the CSII group (24 children
and 35 adults).
A total of 20 patients abandoned the
study: 14 from the PRT group (6 children
and 8 adults) and 6 from the CSII group
(6 adults). The trial ran from May 2006
to May 2008, with the ﬁrst patients re-
cruited in June 2006. Patient character-
istics at baseline were comparable in
both study arms for all analyzable pop-
ulations (Table 1).
A1C levels
In the FAS population, A1C levels were
signiﬁcantlyreducedinbothgroups(PRT
0.81  1.09%, P  0.001; CSII
CGM in transition to pump therapy
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ference in favor of the PRT group failed to
reach statistical signiﬁcance (P  0.087)
(Fig. 1A). Among patients who were fully
compliant with the protocol, however,
the reduction in A1C was signiﬁcantly
greater in the PRT group (PRT 0.96 
0.93%, P  0.001; CSII 0.55  0.93%,
P  0.001; intergroup comparison, P 
0.004) (Fig. 1B).
Glycemic control
In the FAS population, the mean glucose
concentration decreased in both groups
betweenbaselineandstudyend(Table2).
The reduction was signiﬁcantly greater in
the PRT group (30.6  54.0) than
in the CSII group (10.8  39.6) (P 
0.005). Signiﬁcant differences in favor of
the PRT group were also observed with
respect to duration of hyperglycemic
events, in the hyperglycemic area under
the curve per day, in the mean amplitude
of glycemic excursions (MAGE) (15), and
in overall SD of blood glucose values.
Similar trends of improved glycemic vari-
ability were observed in the per protocol
population,althoughsomefailedtoreach
statistical signiﬁcance because of the
small sample size. All hypoglycemia pa-
rameters remained constant and compa-
rable in both groups.
Insulin doses and use
In the FAS population, there was a signif-
icant increase in total daily doses (TDDs)
of insulin between baseline and after 1
monthoftreatmentinboththePRTgroup
(TDD  5.8  12.8 units) and the CSII
group (TDD  2.2  8.4 units, P 
0.032). Likewise, doses increased signiﬁ-
cantly between baseline and study end
(PRT 6.8  17.3 units, CSII 1.5  9.1
units; P  0.036). Patients in the PRT
group delivered bolus doses more fre-
quently after 1 month of treatment (PRT
4.81.5,CSII4.11.2;P0.002)and
at study end (PRT 4.7  1.4, CSII 3.9 
1.4; P  0.005). A higher percentage of
insulindeliveredasbolus(53.810.0%)
in the PRT group versus CSII (49.8 
15.8%) reﬂects these behavioral changes.
In the per protocol population, TDDs
increased between baseline and 1 month
(by 6.1  9.5 units in the PRT group and
by 1.7  7.6 units in the CSII group; P 
0.028), but the difference, although of
comparable magnitude, failed to reach
signiﬁcanceat3and6months.Patientsin
the PRT group delivered bolus doses
more frequently at 3 months (PRT 4.8 
1.2, CSII 4.1  1.2; P  0.002) and at
studyend(PRT4.91.4,CSII3.91.4;
P  0.002). Bolus delivery accounted for
53.3  9.3% of total insulin in the PRT
group versus 49.7  15.9% in the CSII
group.
Ancillary analyses
Betweenthescreeningvisitandtheendof
the study, A1C levels fell signiﬁcantly in
both groups of the FAS population (PRT
1.14  1.21%, P  0.001; CSII 0.57 
0.91%, P  0.001), and the difference in
favorofthePRTgroupcomparedwiththe
CSII group was statistically signiﬁcant
(P0.006).A1Clevelsalsofellintheper
protocol population (PRT 1.23 
1.08%, P  0.001; CSII 0.55  0.90%,
P0.001);theintergroupdifferencewas
again signiﬁcant and in favor of the PRT
group (P  0.001) (Fig. 1).
The probability of failing to comply
with agreed-upon sensor wear was not
constant among different age cohorts.
Analysis according to the age categories
proposed by the Juvenile Diabetes Re-
search Foundation (JDRF) (13) revealed
thehighestsensorcomplianceintheadult
age-group (25 years, n  25, sensor
wear 74.9% of time), followed by the pe-
diatric population (5–14 years, n  14,
sensor wear 68.4% of time). Compliance
was lowest in adolescents (15–25 years,
n  15, sensor wear 52.4% of time). Be-
cause of the small sample size of the age
subgroups, no decrease in A1C was sig-
niﬁcantly different compared with that of
the CSII group.
Ateachvisitaftertreatmentinitiation,
physiciansrecordedwhetherpatientshad
modiﬁed their treatment regimens.
Whereas 20% of patients in the PRT
group reported making modiﬁcations to
their nutritional habits and/or their life-
style, only 10% of patients in the CSII
group did so. In addition, 93.2% of all
patients in the PRT group reported using
CGM data to adjust their insulin doses,
and 59.5% reported that they used CGM
datatomodifytheirresponsestoglycemic
excursions.
Adverse events
Adverseeventdatawerecollectedandan-
alyzed for the safety population. Ten seri-
ousadverseeventswerereported:threein
the PRT group and seven in the CSII
group. Two episodes of ketoacidosis oc-
curred in the PRT group when patients
failed to react to the device’s hyperglyce-
mic alarms. One episode of severe hypo-
glycemia with loss of consciousness also
occurred in the PRT group. In this in-
stance, the device was improperly cali-
brated, and acute alcohol intoxication
may have played a role in the adverse
event. Three episodes of ketoacidosis oc-
curred in the CSII group. The overall ke-
toacidosis rate was 3.2 per 100 patient-
years, and the overall rate of severe
hypoglycemiawas0.64per100patient-
years. Four other serious adverse events
occurred in the CSII group that were
unrelated to the study devices or the
protocol.
CONCLUSIONS — Six months after
transitioning from MDI to pump therapy,
patients with poorly controlled type 1 di-
abetes achieved signiﬁcantly improved
A1C values whether they used a sensor-
augmented insulin pump or a conven-
tional pump (the PRT and CSII groups,
Table 1—Baseline and demographic characteristics
FAS Per protocol
PRT CSII PRT CSII
n 55 60 32 59
Age (years) 28.1  15.1 28.8  16.7 30.9  16.2 28.1  15.7
Age 19 years 33 (60.0) 36 (60.0) 21 (65.6) 35 (59.3)
Male sex 30 (54.5) 34 (56.7) 19 (59.4) 33 (55.9)
Weight (kg) 65.7  17.4 62.6  18.6 66.8  19.9 62.3  18.7
Height (cm) 166.0  12.3 164.6  14.4 166  13.6 164.5  14.5
BMI (kg/m
2) 23.5  4.1 22.5  4.4 23.8  4.7 22.5  4.4
Screening A1C (%) 9.4  1.1 9.3  1.1 9.2  1.0 9.3  1.1
Baseline A1C (%) 9.11  1.28 9.28  1.19 8.9  1.12 9.25  1.19
Baseline MAGE (mg/dl) 188.5 192.9 194.4 192.2
Baseline SD (mg/dl) 74.4 75.1 72.1 75.1
Type 1 diabetes duration (years) 11.2  9.0 12.3  8.8 13.7  10.2 12.2  8.9
Daily insulin doses (units/day) 42.9  17.5 42.2  17.0 40.2  14.8 42.8  16.5
Data are means  SD, n (%), or mean.
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ment within each group was comparable
to published data on the efﬁcacy of pump
therapy (16), conﬁrming the superiority
of pump therapy over MDI in patients
with poorly controlled diabetes.
Among patients who complied with
the study protocol, there was a signiﬁcant
between-group difference favoring the
sensor-augmented over the conventional
insulin pump. However, when protocol-
noncompliantpatientswereincluded,the
A1C improvement was not signiﬁcant be-
tween the PRT and CSII groups.
During the 9-day period between
screening and study baseline, the PRT
group was trained on sensor use and al-
lowed to modify their MDI dosing regi-
mens based on CGM readings. The
decrease observed in A1C levels during
this short interval may represent the im-
mediate beneﬁt of exposure to CGM data,
even in the absence of an insulin pump.
The initial decline in A1C levels seen in
thePRTgroupmayalsoexplaintheblunt-
ing of the difference observed between
baseline and study end. A more meaning-
ful comparison may, therefore, be be-
tween screening and study end.
MAGE and SD calculations revealed a
signiﬁcantly greater reduction in the PRT
group compared with that in the CSII
group for the entire study population.
The improvements in MAGE and SD val-
ues were reached without any increase in
the number or duration of hypoglycemic
events.
Improvements in glycemic control in
the PRT group beyond those seen in the
CSII group may be attributable to alarms
and glucose trend information available
to patients during the study, prompting
patients in the PRT group to engage in
more lifestyle modiﬁcations and insulin
treatment adjustments.
Recent studies reported that CGM
was beneﬁcial in lowering A1C. In the
GuardControl study (12), A1C was re-
duced by 2% in 26% of patients after 3
months of continuous sensor use but not
by intermittent use. Hirsch et al. (14) re-
ported that the effectiveness of sensor-
augmentedpumptherapywascontingent
on patients’ compliance with glucose sen-
sor use. Wearing a CGM sensor 60% of
thetimewasassociatedwithloweredA1C
levels. The JDRF study (13) recently
showed that CGM improved A1C in
adults with well-controlled type 1 diabe-
teswearingthecontinuousglucosesensor
for 83% of the requested time. Although
sensor compliance was less consistent in
other age-groups, compliant patients still
beneﬁted from the technology (13).
Failure to adhere to many aspects of
diabetes management is recognized as an
obstacle for successful treatment in ado-
lescents and young adults (17,18). In the
present study, subjects in the 15- to 24-
year-old age-group had the highest prob-
Figure 1—Change in A1C during the study period. A: A1C levels in the intention-to-treat popu-
lation measured at screening and visits 3, 5, and 6 in the FAS population (n  115). A1C
intergroup visit 3–to–visit 6 ratio: 0.24%, P  0.08; A1C intergroup screening–to–visit 6 ratio:
0.57%, P  0.006. B: A1C levels in the per protocol population (compliant patients, n  91),
A1C intergroup visit 3–to–visit 6 ratio: 0.41%, P  0.004; A1C intergroup screening–to–visit
6 ratio: 0.68%, P  0.001. All values are means  SD.
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sensorprotocol.Ourﬁndingssupportthe
factthatCGMshouldbeusedatleast70%
of the time to improve metabolic control
when pump therapy is initiated and show
that even patients whose diabetes had
been poorly controlled previously with
intensiﬁed MDI regimens may realize
A1C reductions. Patients’ motivation to
use CGM as an adjunct to insulin pump
therapy is crucial for device effectiveness.
Trained health care provider teams
should focus on how to adequately select,
train, manage, and motivate patients to
optimize beneﬁts from CGM.
The high attrition rate of this study
can be considered as a limitation of this
trial and is best explained by the lack of a
run-in period, which could have been
usedtoselectthemostwell-motivatedpa-
tients. In addition, the short duration of
this trial does not provide information on
the long-term impact of the treatment.
In summary, patients who use CGM-
enabled pumps and who wear sensors at
least 70% of the time realize glycemic
beneﬁts beyond those who do not wear
sensors or who use conventional insulin
pumps. Exposure to CGM data, even be-
fore transitioning from MDI to an insulin
pump, can lead to A1C reductions. Re-
duction of hyperglycemia without an in-
creased risk of hypoglycemia can be
achieved by a combination of modiﬁed
insulin administration and lifestyle
changes.
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 Hyperglycemia 190 mg/dl (h/day) 3.5  4.8* 0.7  3.8 4.1  5.1* 0.6  3.8
 Hyperglycemia AUC (mg   dl
1   day
1) 17.1  31.7† 5.8  26.7 19.1  35.5† 5.2  26.5
 Hyperglycemia (episodes/day) 0.2  0.7 0.2  0.7 0.2  0.7 0.2  0.7
 Hypoglycemia 70 mg/dl (h/day) 0.3  1.4 0  1.2 0.6  1.3 0.0  1.2
 Hypoglycemia AUC (mg   dl
1   day
1) 0.4  1.3 0.0  1.8 0.7  1.3 0.0  1.8
 Hypoglycemia (episodes/day) 0.1  0.9 0.1  0.7 0.2  1.0 0.1  0.7
 MAGE (mg/dl) 27.5* 16.2 20.4 16.2
 SD 15.8* 5.7 11.3 5.7
 Daily insulin doses (units/day) 6.8  17.3† 1.5  9.1 6.2  14.8 1.1  8.4
Bolus insulin (%/day) 53.8  10.0 49.8  15.8 53.3  9.3 49.7  15.9
Number of boluses/day 4.7  1.4 3.9  1.4 4.9  1.4 3.9  1.4
Data are means  SD or means. *P  0.005 vs. CSII group. †P  0.05 vs. CSII group.
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